Mayne Pharma Group's (ASX:MYX) board continues to recommend shareholders accept the scheme implementation deed (SID) to be acquired by Cosette Pharmaceuticals via a scheme of arrangement for AU$7.40 per share, according to a Thursday Australian bourse filing.
The board's recommendation follows the receipt of a purported termination notice from Cosette regarding the SID and is subject to the absence of a superior proposal and an independent expert's conclusion that it is in the best interests of shareholders.
The meeting to vote on the scheme is set for June 18, and the second court hearing is set on Sept. 25, the filing added.
Shares of the company rose past 3% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.